A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

PURPOSE: Selinexor is an oral selective inhibitor of exportin-1 (XPO1) with efficacy in various solid and hematologic tumors. We assessed intratumoral penetration, safety, and efficacy of selinexor monotherapy for recurrent glioblastoma. PATIENTS AND METHODS: Seventy-six adults with Karnofsky Perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassman, Andrew B., Wen, Patrick Y., van den Bent, Martin J., Plotkin, Scott R., Walenkamp, Annemiek M.E., Green, Adam L., Li, Kai, Walker, Christopher J., Chang, Hua, Tamir, Sharon, Henegar, Leah, Shen, Yao, Alvarez, Mariano J., Califano, Andrea, Landesman, Yosef, Kauffman, Michael G., Shacham, Sharon, Mau-Sørensen, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810630/
https://www.ncbi.nlm.nih.gov/pubmed/34728525
http://dx.doi.org/10.1158/1078-0432.CCR-21-2225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810630/
https://www.ncbi.nlm.nih.gov/pubmed/34728525
http://dx.doi.org/10.1158/1078-0432.CCR-21-2225

Ejemplares similares